|
|
|
|
A strong biomarker strategy starts with the right clinical questions, analytical platforms, and early context-of-use planning to support efficient, successful drug development.
|
|
|
|
|
Aligning translational pharmacology and targeted bioanalysis early helps researchers connect biochemical data with authentic proof of mechanism. Explore the full asset to discover strategies for optimizing clinical development pathways in central nervous system research.
|
|
|
|
|
Moving innovative science toward patients requires more than a promising laboratory result. Explore how nanoparticles and advanced drug development technologies are translated into practical solutions.
|
|
|
|
|
We Know Development™ is Ardena’s podcast from inside the real work of turning a molecule into a medicine. In Episode 02, host Mira Mikhael asks our formulation scientists and Head of AI where AI genuinely helps, where it still falls short, and how to tell real impact from hype.
|
|
|
|
|
Advanced compaction simulation predicts formulation performance and tablet strength with minimal material, streamlining scale-up and accelerating development to clinical manufacturing.
|
|
|
|
|
A biomarker value is the last link in a chain running from clinical question to analytical plan, proportionate validation, complementary readouts and timely delivery. Designed in isolation, any link can leave sound data mechanistically inadequate for early-phase decisions.
|
|
|
|
|
|
|
|
Ardena Launches Online Biomarker Catalogue: 228 Markers, One Quote Request
|
Before committing samples, sponsors need to know whether a provider has experience with their biomarker, on which platform, and in which matrix and species. Ardena’s new online Biomarker Catalogue answers that upfront: 228 markers in one searchable catalogue and a single quote request from selection to bioanalysis.
|
|
|
|
|
|
|